Logo

AHG

Akso Health Group

AHG

Akso Health Group • NASDAQ
$1.57 ▲ 4.67% (+0.07)
Market Cap $862.24 M
52w High $2.35
52w Low $0.74
Dividend Yield 0%
P/E -3.27
Volume 300
Outstanding Shares 549.20M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $3.922M $82.645M $-67.195M -1.713K% $-0.2 $-624.702K
Q3-2025 $3.922M ▲ $82.645M ▲ $-67.195M ▼ -1.713K% ▼ $-0.2 ▼ $-624.702K ▼
Q2-2025 $3.467M $366.729K $-293.316K -8.46% $-0.004 $-261.888K
Q1-2025 $3.467M ▲ $366.729K ▼ $-293.316K ▲ -8.46% ▲ $-0.004 ▲ $-261.888K ▼
Q4-2024 $760.377K $3.203M $-3.001M -394.615% $-0.14 $0

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $176.23M $214.953M $15.802M $199.119M
Q3-2025 $176.23M ▲ $214.953M ▲ $15.802M ▲ $199.119M ▼
Q2-2025 $91.367M $212.95M $12.298M $200.564M
Q1-2025 $91.367M ▲ $212.95M ▲ $12.298M ▲ $200.564M ▲
Q4-2024 $85.174M $142.018M $3.594M $138.367M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2025 $-67.195M $3.012M $-24.766M $64.335M $0 $3M
Q3-2025 $-67.195M ▼ $3.012M ▲ $-24.766M ▲ $64.335M ▲ $0 $3M ▲
Q2-2025 $-293.316K $-2.423M $-28.19M $33.607M $0 $-2.488M
Q1-2025 $-293.316K ▲ $-2.423M ▼ $-28.19M ▼ $33.607M ▼ $0 ▼ $-2.488M ▼
Q4-2024 $-3.001M $554.452K $-28.125M $65.652M $75.962M $554.452K

Revenue by Products

Product Q1-2014Q2-2014Q3-2021Q2-2023
Interest income
Interest income
 $0 ▲$0 ▲$0 ▲$0 ▲
Commission Services
Commission Services
 $0 ▲$0 ▲$0 ▲$0 ▲
Interest
Interest
 $0 ▲$0 ▲$0 ▲$0 ▲
Home Infusion Therapy
Home Infusion Therapy
 $330.00M ▲$330.00M ▲$0 ▼$0 ▲
Home Respiratory Therapy And Home Medical Equipment
Home Respiratory Therapy And Home Medical Equipment
 $290.00M ▲$280.00M ▼$0 ▼$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Akso Health Group’s income statement shows a business that is still very small in scale and consistently losing money. Revenue is minimal and has stayed that way over several years, while operating losses and net losses recur every year. The company does not yet demonstrate a clear path to stable profitability, and earnings per share have been negative and volatile, suggesting a fragile and still‑forming business model rather than a mature, steady operation.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a modest base of assets and most of that in cash. On the positive side, the company currently carries no meaningful financial debt and has positive equity, which reduces balance‑sheet risk. On the negative side, the overall size of the balance sheet is extremely small, which limits financial flexibility and raises questions about how larger, capital‑intensive plans might be funded without significant external support or dilution.

Cash Flow

Cash Flow Cash flows from operations have hovered around break‑even in recent years, with no notable investment in physical assets. This suggests a lean, asset‑light model today but also indicates that the business is not yet generating strong internal cash to support its ambitious growth plans. The lack of substantial free cash flow means the company may need to rely on future fundraising or partnerships to scale its healthcare and AI initiatives.

Competitive Edge

Competitive Edge Akso Health is trying to carve out a niche by combining a social e‑commerce platform with healthcare services, AI‑driven consultations, and future oncology and vaccine activities. This mix is unusual and potentially powerful if executed well, because it blends a broad consumer channel with specialized medical offerings. However, the strategy is still unproven, the company is very small, and it is targeting highly competitive and heavily regulated healthcare markets, especially in the U.S. The result is a potentially interesting position but without a clearly established, durable competitive moat yet.

Innovation and R&D

Innovation and R&D Innovation is the company’s main story: it is integrating advanced AI (via DeepSeek) into medical consultations, building telemedicine capabilities, and outlining plans for oncology centers and vaccine research. These efforts point to a forward‑looking, technology‑driven vision that goes well beyond a simple e‑commerce model. At the same time, these projects are early, capital‑intensive, and complex, so successful execution will depend on sustained funding, scientific progress, regulatory approvals, and the ability to turn R&D into commercially viable services and products.

Summary

Overall, Akso Health Group looks like an early‑stage, high‑concept platform rather than a mature financial services or healthcare company. The financials show a tiny revenue base, ongoing losses, and limited resources, while the strategy and R&D roadmap are ambitious and wide‑ranging—spanning AI, telemedicine, oncology, and vaccines. The combination of big aspirations, innovative technology, and constrained finances creates a profile with meaningful upside potential if the plan works, but also significant execution and funding risk if growth does not translate into scale and profitability.